Humana (NYSE: HUM) has announced plans to sell its 40% stake in hospice, palliative and personal care provider Gentiva in a deal valued at approximately $900 million.

Humana will sell all, or substantially all, of its minority interest to a consortium of investors, according to an announcement released on Wednesday. The company plans to utilize sale proceeds for general corporate purposes.

Gentiva was formed in 2022 after Humana divested Kindred at Home’s hospice and personal care divisions to private equity firm Clayton, Dubilier & Rice, while retaining a 40% ownership stake. Humana had acquired the remaining interest in Kindred at Home in 2021 and said at the time that it planned to eventually divest the provider’s hospice, palliative and personal health care services.

After the initial divestiture, Humana executives said the company could offer its patients a full continuum of care through its partnership and minority stake in Gentiva. 

Today, Gentiva provides end-of-life care at more than 430 locations across 35 states.

Guggenheim Securities, LLC is acting as Humana’s financial advisor. Fried, Frank, Harris, Shriver & Jacobson LLP and Manatt, Phelps & Phillips LLP are acting as Humana’s legal advisors.

Humana’s divestiture of Gentiva is expected to close in the third quarter of 2026, subject to regulatory approvals and customary closing conditions. The company stated that it does not anticipate a material impact to its 2026 earnings related to this transaction.